Targets › PDCD1L2
1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Aug 2027.
Plays a critical role in induction and maintenance of immune tolerance to self. Acts as a ligand for the inhibitory receptor PDCD1/PD-1, inhibiting T-cell proliferation by blocking cell cycle progression and cytokine production. (UniProt, Q9BQ51)
Open in Phaseline: the race on PDCD1L2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Tianjin Medical University Cancer Institute and Hospital | Ivonescimab (AK112) PD-1/PD-L2 dual checkpoint inhibitor | PDCD1L2, PDCD1 | Phase 2 | ESCC | Aug 2027 |
ESCC (1)
antibody (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.